HSP90 inhibitors with modified toxicity

US9603829B2 · kind B2 · utility

Assignee

• The Regents of the University of Colorado, a Body Corporate · US

Inventors

• David Ross · Cary, US
• David M. Siegal · Franklin Lakes, US
• Christopher J. Moody · Stevenage, GB
• Russell Richard Anthony Kitson · Coalville, GB

Key dates

• Filing date: Nov 14, 2012
• Grant date: Mar 28, 2017
• Expiry date: Nov 14, 2032

Classification

• Technology area (CPC C): Chemistry; Metallurgy
• CPC primary: C07D409/04
• WIPO field: Pharmaceuticals
• WIPO sector: Chemistry

Abstract

The invention provides 19-substituted geldanamycin derivatives, and pharmaceutically acceptable salts thereof that are potent Hsp90 binding agents useful for the treatment of, and/or the amelioration of symptoms of, cancer or neurodegenerative disorders.